Venus Remedies Reports Strong Q4 Results with Significant Growth in Profit and Sales

Venus Remedies, a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results indicate a notable shift in the company's financial landscape, with a revision in its score reflecting these changes.
The Profit Before Tax (PBT) for the quarter stands at Rs 12.94 crore, showcasing a significant year-on-year growth of 138.31%. This positive trend is mirrored in the Profit After Tax (PAT), which reached Rs 11.79 crore, marking a year-on-year increase of 72.2%. Additionally, net sales have also shown a robust performance, amounting to Rs 176.86 crore, which is a 23.32% rise compared to the previous year.

The operating profit margin has reached its highest level in the last five quarters at 10.38%, indicating improved efficiency within the company. Furthermore, the earnings per share (EPS) have also peaked at Rs 14.66, reflecting enhanced profitability for shareholders. The cash and cash equivalents have reached Rs 78.43 crore, the highest in the last six half-yearly periods, suggesting an improvement in short-term liquidity.

These developments contribute to a comprehensive evaluation of Venus Remedies, highlighting a positive trajectory in its financial performance.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.